Janssen/Pharmacyclics’ ibrutinib shows continued survival benefit in chronic lymphocytic leukaemia

17 Jun 2024
pmlive.com
Phase 3Clinical Result
Janssen/Pharmacyclics’ ibrutinib shows continued survival benefit in chronic lymphocytic leukaemia
Preview
Source: PMLiVE
Janssen and Pharmacyclics’ ibrutinib has demonstrated a significant and sustained progression-free and overall survival benefit in patients with previously untreated chronic lymphocytic leukaemia (CLL), according to new long-term results shared by the Johnson & Johnson company.
Affecting approximately 4.92 per 100,000 people every year in Europe, CLL is typically a slow-growing blood cancer of the white blood cells.
Despite patient outcomes improving significantly over the last few decades, CLL is still characterised by consecutive episodes of disease progression and patients are often prescribed multiple lines of therapy as they relapse or become resistant to treatments.
Administered orally once daily, ibrutinib is designed to block the BTK protein needed by normal and abnormal B-cells to multiply and spread.
The drug already holds approvals to treat treatment-naïve and pretreated CLL, as well as certain patients with mantle cell lymphoma and Waldenström’s macroglobulinaemia.
The phase 3 RESONATE-2 trial has been comparing ibrutinib monotherapy against chlorambucil for up to 12 cycles in previously untreated CLL patients aged 65 years and older.
The results, presented at this year’s European Hematology Association Congress, showed a median progression-free survival of 8.9 years in the ibrutinib arm versus 1.3 years in the chlorambucil cohort.
With up to ten years of follow-up, median overall survival had not been reached with ibrutinib and 27% of patients in the study remained on ibrutinib.
The drug was also found to be well tolerated as a long-term treatment and no new safety signals were observed.
Commenting on the latest results, clinical study investigator, Alessandra Tedeschi, Niguarda Hospital, said: “When ibrutinib was first introduced more than ten years ago, it changed the course of CLL treatment, and today it remains a central part of the standard of care for patients living with B-cell malignancies.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.